1,167
Views
5
CrossRef citations to date
0
Altmetric
Back Matter

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

ORCID Icon, , , , , , , , & show all
Article: 1708066 | Received 18 Sep 2019, Accepted 26 Oct 2019, Published online: 26 Dec 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ahmad A Tarhini, Ila Joshi & Fiona Garner. (2021) Sargramostim and Immune Checkpoint Inhibitors: Combinatorial Therapeutic Studies in Metastatic Melanoma. Immunotherapy 13:12, pages 1011-1029.
Read now
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now

Articles from other publishers (3)

Han Ying Wang, You-Chiun Chang, Che-Wei Hu, Chia-Yi Kao, Yao-An Yu, See-Khai Lim & Kurt Yun Mou. (2021) Development of a Novel Cytokine Vehicle Using Filamentous Phage Display for Colorectal Cancer Treatment. ACS Synthetic Biology 10:8, pages 2087-2095.
Crossref
Kim M. van Pul, Marieke F. Fransen, Rieneke van de Ven & Tanja D. de Gruijl. (2021) Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. Frontiers in Immunology 12.
Crossref
Bas D Koster, Marta López González, Mari FCM van den Hout, Annelies W Turksma, Berbel JR Sluijter, Barbara G Molenkamp, Paul AM van Leeuwen, Saskia Vosslamber, Rik J Scheper, Alfons JM van den Eertwegh, M Petrousjka van den Tol, Ekaterina J Jordanova & Tanja D de Gruijl. (2021) T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A + CD141 + cDC1 and CD14 + antigen-presenting cell recruitment . Journal for ImmunoTherapy of Cancer 9:3, pages e001962.
Crossref